Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
Sign Up to like & getrecommendations! Published in 2017 at "Protein & Cell"
DOI: 10.1007/s13238-017-0489-0
Abstract: T cells genetically engineered to express CARs specific for CD19 have shown breakthrough clinical successes in patients with B-cell lymphoid malignancies in recent years (Grupp SA et al., 2013; Kalos M et al., 2011; Maude… read more here.
Keywords: gpc3 car; car cells; gpc3; cell ... See more keywords
Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Immunology Research"
DOI: 10.1155/2021/1782728
Abstract: Background Chimeric antigen receptor-modified T cell (CAR-T) therapy has great potential for treating malignant tumors, especially hematological malignancies. However, the therapeutic effect of solid tumors is limited. One of the most important factors is the… read more here.
Keywords: car cells; gpc3 car; car; aav ccl19 ... See more keywords